BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 31698191)

  • 1. Generation of a PARK2 homozygous knockout induced pluripotent stem cell line (GIBHi002-A-1) with two common isoforms abolished.
    Zhang M; Ibañez DP; Fan W; Liu H; Zhong X; Wang X; Li Y; Md Abdul M; Li W; Li Y; Ward C; Chen S; Wang D; Qin B; Esteban MA; Zhao P; Luo Z
    Stem Cell Res; 2019 Dec; 41():101602. PubMed ID: 31698191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The endoplasmic reticulum-mitochondria interface is perturbed in PARK2 knockout mice and patients with PARK2 mutations.
    Gautier CA; Erpapazoglou Z; Mouton-Liger F; Muriel MP; Cormier F; Bigou S; Duffaure S; Girard M; Foret B; Iannielli A; Broccoli V; Dalle C; Bohl D; Michel PP; Corvol JC; Brice A; Corti O
    Hum Mol Genet; 2016 Jul; 25(14):2972-2984. PubMed ID: 27206984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of an induced pluripotent stem cell line (CSC-44) from a Parkinson's disease patient carrying a compound heterozygous mutation (c.823C>T and EX6 del) in the PARK2 gene.
    Marote A; Pomeshchik Y; Goldwurm S; Collin A; Lamas NJ; Pinto L; Salgado AJ; Roybon L
    Stem Cell Res; 2018 Mar; 27():90-94. PubMed ID: 29353703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of three induced pluripotent stem cell lines from a Parkinson's disease patient with mutant PARKIN (p. C253Y).
    Tariq M; Liu H; Ibañez DP; Li Y; Chen S; Jiang M; Fan W; Zhao P; Luo Z; Wang D; Kanwal S
    Stem Cell Res; 2020 May; 45():101822. PubMed ID: 32387897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of an induced pluripotent stem cell line (EURACi005-A) from a Parkinson's disease patient carrying a homozygous exon 3 deletion in the PRKNgene.
    Zanon A; Riekschnitz D; von Troyer M; Volpato C; Picard A; Cantaloni C; Di Segni M; Silipigni R; Pramstaller PP; Hicks AA; Pichler I
    Stem Cell Res; 2019 Dec; 41():101624. PubMed ID: 31715428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of bioactive metabolites in human iPSC-derived dopaminergic neurons with PARK2 mutation: Altered mitochondrial and energy metabolism.
    Okarmus J; Havelund JF; Ryding M; Schmidt SI; Bogetofte H; Heon-Roberts R; Wade-Martins R; Cowley SA; Ryan BJ; Færgeman NJ; Hyttel P; Meyer M
    Stem Cell Reports; 2021 Jun; 16(6):1510-1526. PubMed ID: 34048689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitochondrial alterations by PARKIN in dopaminergic neurons using PARK2 patient-specific and PARK2 knockout isogenic iPSC lines.
    Shaltouki A; Sivapatham R; Pei Y; Gerencser AA; Momčilović O; Rao MS; Zeng X
    Stem Cell Reports; 2015 May; 4(5):847-59. PubMed ID: 25843045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of hiPSCs (JUCGRMi003-A) from a patient with Parkinson's disease with PARK2 mutation.
    Ishikawa KI; Okuzumi A; Yoshino H; Hattori N; Akamatsu W
    Stem Cell Res; 2024 Apr; 76():103323. PubMed ID: 38309147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of an induced pluripotent stem cell line (GIBHi003-A) from a Parkinson's disease patient with mutant PINK1 (p. I368N).
    Abdul MM; Ibañez DP; Zhao P; Liu H; Zhong X; Li Y; Zhang M; Li W; Li Y; Ward C; Chen S; Wang D; Qin B; Esteban MA; Wang X; Fan W; Luo Z
    Stem Cell Res; 2019 Dec; 41():101607. PubMed ID: 31778937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of the iPSC line FINi002-A from a male Parkinson's disease patient carrying compound heterozygous mutations in the PRKN gene.
    Pavan C; Jin J; Jong S; Strbenac D; Davis RL; Sue CM; Johnston J; Lynch T; Halliday G; Kirik D; Parish CL; Thompson LH; Ovchinnikov DA
    Stem Cell Res; 2023 Dec; 73():103211. PubMed ID: 37890334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lysosomal perturbations in human dopaminergic neurons derived from induced pluripotent stem cells with PARK2 mutation.
    Okarmus J; Bogetofte H; Schmidt SI; Ryding M; García-López S; Ryan BJ; Martínez-Serrano A; Hyttel P; Meyer M
    Sci Rep; 2020 Jun; 10(1):10278. PubMed ID: 32581291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of induced pluripotent stem cells (NIMHi015-A) from a Parkinson's Disease patient harbouring a homozygous Exon 3 deletion in the PRKN gene.
    Banerjee R; Ghanty R; Jagtap S; Holla V; Kamble N; Yadav R; Pal PK; Datta I
    Stem Cell Res; 2024 Jun; 77():103440. PubMed ID: 38739971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parkin-associated Parkinson's disease.
    von Coelln R; Dawson VL; Dawson TM
    Cell Tissue Res; 2004 Oct; 318(1):175-84. PubMed ID: 15503153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perturbations in RhoA signalling cause altered migration and impaired neuritogenesis in human iPSC-derived neural cells with PARK2 mutation.
    Bogetofte H; Jensen P; Okarmus J; Schmidt SI; Agger M; Ryding M; Nørregaard P; Fenger C; Zeng X; Graakjær J; Ryan BJ; Wade-Martins R; Larsen MR; Meyer M
    Neurobiol Dis; 2019 Dec; 132():104581. PubMed ID: 31445161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenotypical Differences in Neuronal Cultures Derived via Reprogramming the Fibroblasts from Patients Carrying Mutations in Parkinsonian Genes LRRK2 and PARK2.
    Konovalova EV; Novosadova EV; Grivennikov IA; Illarioshkin SN
    Bull Exp Biol Med; 2015 Oct; 159(6):772-5. PubMed ID: 26519280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LRRK2 impairs PINK1/Parkin-dependent mitophagy via its kinase activity: pathologic insights into Parkinson's disease.
    Bonello F; Hassoun SM; Mouton-Liger F; Shin YS; Muscat A; Tesson C; Lesage S; Beart PM; Brice A; Krupp J; Corvol JC; Corti O
    Hum Mol Genet; 2019 May; 28(10):1645-1660. PubMed ID: 30629163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Etiology and pathogenesis of Parkinson's disease: from mitochondrial dysfunctions to familial Parkinson's disease].
    Hattori N
    Rinsho Shinkeigaku; 2004; 44(4-5):241-62. PubMed ID: 15287506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternative splicing generates different parkin protein isoforms: evidences in human, rat, and mouse brain.
    Scuderi S; La Cognata V; Drago F; Cavallaro S; D'Agata V
    Biomed Res Int; 2014; 2014():690796. PubMed ID: 25136611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of homozygous PRKN, PINK1 and double PINK1/PRKN knockout cell lines from healthy induced pluripotent stem cells using CRISPR/Cas9 editing.
    Chen CX; You Z; Abdian N; Sirois J; Shlaifer I; Tabatabaei M; Boivin MN; Gaborieau L; Karamchandani J; Beitel LK; Fon EA; Durcan TM
    Stem Cell Res; 2022 Jul; 62():102806. PubMed ID: 35561458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parkin and PINK1 Patient iPSC-Derived Midbrain Dopamine Neurons Exhibit Mitochondrial Dysfunction and α-Synuclein Accumulation.
    Chung SY; Kishinevsky S; Mazzulli JR; Graziotto J; Mrejeru A; Mosharov EV; Puspita L; Valiulahi P; Sulzer D; Milner TA; Taldone T; Krainc D; Studer L; Shim JW
    Stem Cell Reports; 2016 Oct; 7(4):664-677. PubMed ID: 27641647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.